The latest B7-H4 ADC shows activity only in biomarker-positive patients.

And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.

The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.

An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.

But the timeline for a US green light is less clear, and the group has a cash crisis.

First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.